The connection between aberrant cell death and cancer1sparked a detailed understanding of the mitochondrial pathway to apoptosis2and led to the first BCL-2 antagonist approved for cancer therapy, venetoclax3,4. BCL-2 is the founding member of the pro-survival class of proteins that includes BCL-...